HTG Molecular Diagnostics and Oncologie, Inc. Complete Master Agreement to Partner on Biomarker Development for Immuno-oncology Drug Development
“We are honored to be working with Oncologie on biomarker development programs for their innovative pipeline of Immuno-oncology assets,” stated TJ Johnson HTG Chief Executive Officer. “HTG is committed to the development of NGS-based precision diagnostics to support biomarker driven drug development, and we share a common focus with Oncologie in the field of Immuno-oncology.”
Laura Benjamin Ph.D., Oncologie Chief Executive Officer and founder added, “We believe HTG’s technology and assay development capabilities will assist our clinical development efforts as we strive to bring innovative new medicines to cancer patients globally.”
ONCOLOGIE is an oncology therapeutics company committed to delivering better outcomes for cancer patients through an improved understanding of which patients will benefit from each drug in the pipeline. The current pipeline is focused on mid-stage clinical programs that modify the immune system to enhance efficacy of current standards of care and emerging immunotherapy agents. Headquartered in
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected development of biomarkers under the master agreement with Oncologie. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that development activities expected under the Oncologie master agreement may not be performed as expected, or at all, risks inherent in the development of custom profiling assays for specific indications, risks associated with the utility of our profiling panels, instruments and solutions, and risks associated with our ability to successfully manufacture and supply our products. These and other factors are described in greater detail in our filings with the
LifeSci Advisors, LLC
Phone: (617) 535-7742
Phone: (520) 547-2827 x130
Phone: (781) 907-7810
Source: HTG Molecular Diagnostics, Inc.